Colorectal Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Colorectal Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 6 (June)

1. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence.
   J Natl Cancer Inst, 97(11): 846-53. [Abstract] [Full-text]
2. Folate and its preventive potential in colorectal carcinogenesis. How strong is the biological and epidemiological evidence?
   Crit Rev Oncol Hematol, 55(1): 13-36. [Abstract] [Full-text]
3. Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?
   Crit Rev Oncol Hematol, 55(1): 67-81. [Abstract] [Full-text]
4. Sentinel nodes are identifiable in formalin-fixed specimens after surgeon-performed ex vivo sentinel lymph node mapping in colorectal cancer.
   Ann Surg Oncol, 12(6): 504-9. [Abstract] [Full-text]
5. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression.
   J Cell Physiol, 204(2): 484-8. [Abstract] [Full-text]
6. Germline susceptibility to colorectal cancer due to base-excision repair gene defects.
   Am J Hum Genet, 77(1): 112-9. [Abstract] [Full-text]
7. High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies.
   Clin Cancer Res, 11(11): 4234-40. [Abstract] [Full-text]
8. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
   Clin Cancer Res, 11(11): 4090-6. [Abstract] [Full-text]
9. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
   Clin Cancer Res, 11(11): 4067-73. [Abstract] [Full-text]
10. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer.
    Cancer Res, 65(11): 4881-7. [Abstract] [Full-text]
11. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions.
    Cancer Res, 65(11): 4728-38. [Abstract] [Full-text]
12. Centromere protein H is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy.
    Cancer Res, 65(11): 4683-9. [Abstract] [Full-text]
13. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility.
    Cancer Res, 65(11): 4645-52. [Abstract] [Full-text]
14. Mutations in two short noncoding mononucleotide repeats in most microsatellite-unstable colorectal cancers.
    Cancer Res, 65(11): 4607-13. [Abstract] [Full-text]
15. Functional analysis of PIK3CA gene mutations in human colorectal cancer.
    Cancer Res, 65(11): 4562-7. [Abstract] [Full-text]
16. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
    J Endocrinol, 185(3): 577-92. [Abstract] [Full-text]
17. Noninvasive testing for colorectal cancer: a review.
    Am J Gastroenterol, 100(6): 1393-403. [Abstract] [Full-text]
18. Genetic analyses in consecutive israeli jewish colorectal cancer patients.
    Am J Gastroenterol, 100(6): 1376-80. [Abstract] [Full-text]
19. Will a 5-ASA a day keep the cancer (and dysplasia) away?
    Am J Gastroenterol, 100(6): 1354-6. [Abstract] [Full-text]
20. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
    Am J Gastroenterol, 100(6): 1345-53. [Abstract] [Full-text]
21. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.
    Am J Gastroenterol, 100(6): 1283-9. [Abstract] [Full-text]
22. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy.
    J Clin Invest, 115(6): 1492-502. [Abstract] [Full-text]
23. Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis.
    Oncogene, 24(24): 3932-41. [Abstract] [Full-text]
24. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations.
    Oncogene, 24(24): 3987-94. [Abstract] [Full-text]
25. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes.
    Oncogene, 24(24): 3995-8. [Abstract] [Full-text]
26. CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype.
    Carcinogenesis, 26(6): 1152-6. [Abstract] [Full-text]
27. Butyrate may enhance toxicological defence in primary, adenoma and tumor human colon cells by favourably modulating expression of glutathione S-transferases genes, an approach in nutrigenomics.
    Carcinogenesis, 26(6): 1064-76. [Abstract] [Full-text]
28. CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use, and risk for colorectal adenoma.
    Carcinogenesis, 26(6): 1122-8. [Abstract] [Full-text]
29. Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells.
    Photochem Photobiol, 81(2): 306-13. [Abstract] [Full-text]
30. Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study.
    Onkologie, 28(6): 347-50. [Abstract] [Full-text]
31. Postoperative complications in patients irradiated pre-operatively for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs chemoradiation.
    Colorectal Dis, 7(4): 410-6. [Abstract] [Full-text]
32. The impact of bone marrow micrometastases on metastatic disease-free survival in patients with colorectal carcinoma.
    Colorectal Dis, 7(4): 406-9. [Abstract] [Full-text]
33. Almost all five year disease free survivors are cured following rectal cancer surgery, but longer term follow-up detects some late local and systemic recurrences.
    Colorectal Dis, 7(4): 403-5. [Abstract] [Full-text]
34. The prevalence of iron deficiency among patients presenting with colorectal cancer.
    Colorectal Dis, 7(4): 398-402. [Abstract] [Full-text]
35. Pre-operative assessment of extramural invasion and sphincteral involvement in rectal cancer by magnetic resonance imaging with phased-array coil.
    Colorectal Dis, 7(4): 387-93. [Abstract] [Full-text]
36. Comparison of circumferential margin involvement between restorative and nonrestorative resections for rectal cancer.
    Colorectal Dis, 7(4): 369-74. [Abstract] [Full-text]
37. The ileo neo rectal anastomosis (INRA) in patients with familial adenomatous polyposis: clinical results at two years.
    Colorectal Dis, 7(4): 354-9. [Abstract] [Full-text]
38. A prospective analysis of extended endoscopic mucosal resection for large rectal villous adenomas: an alternative technique to transanal endoscopic microsurgery.
    Colorectal Dis, 7(4): 339-44. [Abstract] [Full-text]
39. Is prophylactic colectomy indicated in patients with MYH-associated polyposis?
    Colorectal Dis, 7(4): 327-31. [Abstract] [Full-text]
40. Colorectal adenomas with a low frequency of ki-ras mutations: a sample from a population with a low mortality rate from colorectal cancer.
    Colorectal Dis, 7(4): 323-6. [Abstract] [Full-text]
41. Preoperative chemotherapy and radiotherapy for locally advanced rectal cancer.
    ANZ J Surg, 75(5): 286-91. [Abstract] [Full-text]
42. Performing a colonoscopy 12 months after surgery for colorectal neoplasia.
    ANZ J Surg, 75(5): 282-5. [Abstract] [Full-text]
43. Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions.
    Dis Colon Rectum, 48(5): 1042-54. [Abstract] [Full-text]
44. Endorectal ultrasound in the management of patients with malignant rectal polyps.
    Dis Colon Rectum, 48(5): 910-6; discussion 916-7. [Abstract] [Full-text]
45. Preoperative serum vascular endothelial growth factor is not a marker for subsequent recurrence during long-term follow-up of colorectal cancer patients.
    Dis Colon Rectum, 48(5): 1070-5. [Abstract] [Full-text]
46. A scoring system for the strength of a family history of colorectal cancer.
    Dis Colon Rectum, 48(5): 889-96. [Abstract] [Full-text]
47. Operative salvage for locoregional recurrent colon cancer after curative resection: an analysis of 100 cases.
    Dis Colon Rectum, 48(5): 897-909. [Abstract] [Full-text]
48. Evaluation of tumor cell dissociation as a predictive marker of lymph node metastasis in submucosal invasive colorectal carcinoma.
    Dis Colon Rectum, 48(5): 938-45. [Abstract] [Full-text]
49. Sacral neuromodulation in treatment of fecal incontinence following anterior resection and chemoradiation for rectal cancer.
    Dis Colon Rectum, 48(5): 1027-36. [Abstract] [Full-text]
50. Preoperative radiotherapy improves outcome in recurrent rectal cancer.
    Dis Colon Rectum, 48(5): 918-28. [Abstract] [Full-text]
51. Surgery for locally recurrent rectal cancer.
    Dis Colon Rectum, 48(5): 929-37. [Abstract] [Full-text]
52. Sensitization of colon cancer cell lines to butyrate-mediated proliferation inhibition by combined application of indomethacin and nordihydroguaiaretic acid.
    Cancer Detect Prev, 29(3): 276-85. [Abstract] [Full-text]
53. Automated functional image-guided radiation treatment planning for rectal cancer.
    Int J Radiat Oncol Biol Phys, 62(3): 893-900. [Abstract] [Full-text]
54. Comparison of the belly board device method and the distended bladder method for reducing irradiated small bowel volumes in preoperative radiotherapy of rectal cancer patients.
    Int J Radiat Oncol Biol Phys, 62(3): 769-75. [Abstract] [Full-text]
55. Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancer.
    Int J Radiat Oncol Biol Phys, 62(3): 761-8. [Abstract] [Full-text]
56. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer.
    Int J Radiat Oncol Biol Phys, 62(3): 752-60. [Abstract] [Full-text]
57. Interleukin-5 potentiates the growth response of Caco-2 cells to IGF-II: a role in colonic carcinogenesis complicating ulcerative colitis?
    Growth Horm IGF Res, 15(3): 215-22. [Abstract] [Full-text]
58. Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer.
    Acad Radiol, 12(6): 722-7. [Abstract] [Full-text]
59. Association between subject factors and colorectal cancer screening participation in Ontario, Canada.
    Cancer Detect Prev, 29(3): 221-6. [Abstract] [Full-text]
60. Dietary fibres as "prebiotics": implications for colorectal cancer.
    Mol Nutr Food Res, 49(6): 609-19. [Abstract] [Full-text]
61. Dietary fibre and colorectal cancer: a model for environment--gene interactions.
    Mol Nutr Food Res, 49(6): 571-84. [Abstract] [Full-text]
62. Adenoma with gastric differentiation (so-called pyloric gland adenoma) in a heterotopic gastric corpus mucosa in the rectum.
    Virchows Arch, 446(5): 542-5. [Abstract] [Full-text]
63. HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin.
    Cancer Chemother Pharmacol, 56(2): 212-20. [Abstract] [Full-text]
64. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.
    Gene Ther, 12(12): 1011-8. [Abstract] [Full-text]
65. A unique gene having homology with the kinesin family member 18A encodes a tumour-associated antigen recognised by cytotoxic T lymphocytes from HLA-A2+ colon cancer patients.
    Eur J Cancer, 41(9): 1323-30. [Abstract] [Full-text]
66. Desmoid tumors and deep fibromatoses.
    Hematol Oncol Clin North Am, 19(3): 565-71, vii-viii. [Abstract] [Full-text]
67. Combined electric field and ultrasound therapy as a novel anti-tumour treatment.
    Eur J Cancer, 41(9): 1339-48. [Abstract] [Full-text]
68. Genotoxicity of 4-hydroxy-2-nonenal in human colon tumor cells is associated with cellular levels of glutathione and the modulation of glutathione S-transferase A4 expression by butyrate.
    Toxicol Sci, 86(1): 27-35. [Abstract] [Full-text]
69. The SRC-induced mesenchymal state in late-stage colon cancer cells.
    Cells Tissues Organs, 179(1): 73-80. [Abstract] [Full-text]
70. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin.
    Cells Tissues Organs, 179(1): 56-65. [Abstract] [Full-text]
71. Dietary intake of folate and riboflavin, MTHFR C677T genotype, and colorectal adenoma risk: a Dutch case-control study.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1562-6. [Abstract] [Full-text]
72. Is the association with fiber from foods in colorectal cancer confounded by folate intake?
    Cancer Epidemiol Biomarkers Prev, 14(6): 1552-6. [Abstract] [Full-text]
73. Evidence for an association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk of colorectal cancer.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1460-3. [Abstract] [Full-text]
74. Project PREVENT: a randomized trial to reduce multiple behavioral risk factors for colon cancer.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1453-9. [Abstract] [Full-text]
75. Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1402-10. [Abstract] [Full-text]
76. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1394-401. [Abstract] [Full-text]
77. Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.
    Chemotherapy, 51(2): 111-5. [Abstract] [Full-text]
78. Colorectal carcinoma screening among Hispanics and non-Hispanic whites in a rural setting.
    Cancer, 103(12): 2491-8. [Abstract] [Full-text]
79. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma.
    Cancer, 103(12): 2435-46. [Abstract] [Full-text]
80. Abdominal obesity, insulin resistance, and colon carcinogenesis are increased in mutant mice lacking gastrin gene expression.
    Cancer, 103(12): 2643-53. [Abstract] [Full-text]
81. Colorectal cancer and the CHEK2 1100delC mutation.
    Genes Chromosomes Cancer, 43(4): 377-82. [Abstract] [Full-text]
82. Zinc finger protein overexpressed in colon carcinoma interacts with the telomeric protein hRap1.
    J Cell Biochem, 95(4): 763-8. [Abstract] [Full-text]
83. Increased expression of calcineurin in human colorectal adenocarcinomas.
    J Cell Biochem, 95(4): 731-9. [Abstract] [Full-text]
84. Dietary intakes of fruit, vegetables, and fiber, and risk of colorectal cancer in a prospective cohort of women (United States).
    Cancer Causes Control, 16(3): 225-33. [Abstract] [Full-text]
85. Early life events and later risk of colorectal cancer: age-period-cohort modelling in the Nordic countries and Estonia.
    Cancer Causes Control, 16(3): 215-23. [Abstract] [Full-text]
86. Hereditary colorectal cancer syndromes.
    Cancer Causes Control, 16(3): 201-13. [Abstract] [Full-text]
87. ERbeta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components.
    Endocr Relat Cancer, 12(2): 455-69. [Abstract] [Full-text]
88. Measurement of psychological factors associated with genetic testing for hereditary breast, ovarian and colon cancers.
    Fam Cancer, 4(2): 195-206. [Abstract] [Full-text]
89. APC and beta-catenin protein expression patterns in HNPCC-related endometrial and colorectal cancers.
    Fam Cancer, 4(2): 187-90. [Abstract] [Full-text]
90. The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families.
    Fam Cancer, 4(2): 183-6. [Abstract] [Full-text]
91. SISE matters: the sum of information on seventy-yr-old equivalents measures pedigree information content when assessing the risk of HNPCC in a family.
    Fam Cancer, 4(2): 169-75. [Abstract] [Full-text]
92. Informing one's family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study.
    Fam Cancer, 4(2): 163-7. [Abstract] [Full-text]
93. Referrals of patients to colorectal cancer genetics services in south-east Scotland.
    Fam Cancer, 4(2): 151-61. [Abstract] [Full-text]
94. Screening for exonic copy number mutations at MSH2 and MLH1 by MAPH.
    Fam Cancer, 4(2): 145-9. [Abstract] [Full-text]
95. An unusual case of Turcot's syndrome associated with ileal adenocarcinoma, intestinal non-Hodgkin's lymphoma, and duodenal adenocarcinoma. Review of the classification and genetic basis of Turcot's syndrome.
    Fam Cancer, 4(2): 139-43. [Abstract] [Full-text]
96. Abdominal desmoid in familial adenomatous polyposis presenting as a pancreatic cystic lesion.
    Fam Cancer, 4(2): 135-8. [Abstract] [Full-text]
97. A comparison of the phenotype and genotype in adenomatous polyposis patients with and without a family history.
    Fam Cancer, 4(2): 127-33. [Abstract] [Full-text]
98. Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations.
    Fam Cancer, 4(2): 121-6. [Abstract] [Full-text]
99. In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy.
    Gut, 54(7): 950-4. [Abstract] [Full-text]
100. Importance of N- and C-terminal regions of gastrin-Gly for preferential binding to high and low affinity gastrin-Gly receptors.
     Peptides, 26(7): 1207-12. [Abstract] [Full-text]
101. Large genomic aberrations in MSH2 and MLH1 genes are frequent in Chinese colorectal cancer.
     Cancer Genet Cytogenet, 160(1): 61-7. [Abstract] [Full-text]
102. High participation rates are not necessary for cost-effective colorectal cancer screening.
     J Med Screen, 12(2): 96-102. [Abstract] [Full-text]
103. Acceptance of flexible sigmoidoscopy and colonoscopy for screening and surveillance in colorectal cancer prevention.
     J Med Screen, 12(2): 89-95. [Abstract] [Full-text]
104. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial.
     J Med Screen, 12(2): 83-8. [Abstract] [Full-text]
105. Colonic adenocarcinoma and stones in an Indiana pouch.
     Int J Urol, 12(4): 412-3. [Abstract] [Full-text]
106. Laparoscopic environmental changes during surgery enhance the invasive potential of tumours.
     Tumour Biol, 26(2): 94-102. [Abstract] [Full-text]
107. Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway.
     J Biol Chem, 280(24): 22856-67. [Abstract] [Full-text]
108. Frequency of hereditary non-polyposis colorectal cancer among Uruguayan patients with colorectal cancer.
     Clin Genet, 68(1): 80-7. [Abstract] [Full-text]
109. Differential expression of proteins in response to ceramide-mediated stress signal in colon cancer cells by 2-D gel electrophoresis and MALDI-TOF-MS.
     J Proteome Res, 4(3): 870-80. [Abstract] [Full-text]
110. Modulation of CDK2-AP1 (p12(DOC-1)) expression in human colorectal cancer.
     Oncogene, 24(22): 3657-68. [Abstract] [Full-text]
111. Gene expression signatures for colorectal cancer microsatellite status and HNPCC.
     Br J Cancer, 92(12): 2240-8. [Abstract] [Full-text]
112. p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis.
     Br J Cancer, 92(12): 2114-21. [Abstract] [Full-text]
113. Hemochromatosis gene mutations, body iron stores, dietary iron, and risk of colorectal adenoma in women.
     J Natl Cancer Inst, 97(12): 917-26. [Abstract] [Full-text]
114. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition.
     J Natl Cancer Inst, 97(12): 906-16. [Abstract] [Full-text]
115. Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study.
     J Natl Cancer Inst, 97(12): 896-905. [Abstract] [Full-text]
116. Expression of cell survival/death genes: Bcl-2 and Bax at the rate of colon cancer prognosis.
     Biochim Biophys Acta, 1741(1): 25-9. [Abstract] [Full-text]
117. HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation.
     Br J Cancer, 92(12): 2233-9. [Abstract] [Full-text]
118. Metallothionein crypt-restricted immunopositivity indices (MTCRII) correlate with aberrant crypt foci (ACF) in mouse colon.
     Br J Cancer, 92(12): 2160-5. [Abstract] [Full-text]
119. Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans.
     Biochim Biophys Acta, 1741(1): 215-23. [Abstract] [Full-text]
120. LPA2 receptor mediates mitogenic signals in human colon cancer cells.
     Am J Physiol Cell Physiol, 289(1): C2-11. [Abstract] [Full-text]
121. Stability of phosphoprotein as a biological marker of tumor signaling.
     Clin Cancer Res, 11(12): 4338-40. [Abstract] [Full-text]
122. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
     Cancer Res, 65(12): 5358-64. [Abstract] [Full-text]
123. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone from cigarette smoke stimulates colon cancer growth via beta-adrenoceptors.
     Cancer Res, 65(12): 5272-7. [Abstract] [Full-text]
124. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells.
     Cancer Res, 65(12): 5238-47. [Abstract] [Full-text]
125. Cleavage of carcinoembryonic antigen induces metastatic potential in colorectal carcinoma.
     Biochem Biophys Res Commun, 333(1): 223-9. [Abstract] [Full-text]
126. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy.
     Dis Colon Rectum, 48(6): 1176-81. [Abstract] [Full-text]
127. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum.
     Dis Colon Rectum, 48(6): 1161-8. [Abstract] [Full-text]
128. Neoadjuvant therapy for rectal cancer: improved tumor response, local recurrence, and overall survival in nonanemic patients.
     Dis Colon Rectum, 48(6): 1153-60. [Abstract] [Full-text]
129. hTERT gene copy number is not associated with hTERT RNA expression or telomerase activity in colorectal cancer.
     Int J Cancer, 116(3): 395-400. [Abstract] [Full-text]
130. Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer.
     Int J Cancer, 116(3): 428-32. [Abstract] [Full-text]
131. Connexin43 is overexpressed in Apc(Min/+)-mice adenomas and colocalises with COX-2 in myofibroblasts.
     Int J Cancer, 116(3): 351-8. [Abstract] [Full-text]
132. 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways.
     Mol Pharmacol, 68(1): 119-28. [Abstract] [Full-text]
133. Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case.
     Dis Colon Rectum, 48(6): 1316-9. [Abstract] [Full-text]
134. Surgical salvage of recurrent rectal cancer after transanal excision.
     Dis Colon Rectum, 48(6): 1169-75. [Abstract] [Full-text]
135. Management of anal canal cancer.
     Dis Colon Rectum, 48(6): 1301-15. [Abstract] [Full-text]
136. Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis.
     Dis Colon Rectum, 48(6): 1182-92. [Abstract] [Full-text]
137. Aberrant methylation of HLTF, SOCS-1, and CDH13 genes is shown in colorectal cancers without lymph node metastasis.
     Dis Colon Rectum, 48(6): 1282-6. [Abstract] [Full-text]
138. Genetic testing for germline mutations of the APC gene in patients with apparently sporadic desmoid tumors but a family history of colorectal carcinoma.
     Dis Colon Rectum, 48(6): 1275-81. [Abstract] [Full-text]
139. Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol.
     Oncogene, 24(26): 4301-10. [Abstract] [Full-text]
140. Screening methods for high-grade dysplasia in patients with anal condyloma.
     J Surg Res, 127(1): 8-13. [Abstract] [Full-text]
141. Oestrogen receptor-related receptor alpha (ERRalpha) and oestrogen receptors (ERalpha and ERbeta) exhibit different gene expression in human colorectal tumour progression.
     Eur J Cancer, 41(10): 1487-94. [Abstract] [Full-text]
142. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
     Ann Oncol, 16(7): 1123-32. [Abstract] [Full-text]
143. Tangutorine induces p21 expression and abnormal mitosis in human colon cancer HT-29 cells.
     Biochem Pharmacol, 70(2): 287-99. [Abstract] [Full-text]
144. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer.
     Ann Oncol, 16(7): 1140-6. [Abstract] [Full-text]
145. Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer.
     Ann Surg Oncol, 12(7): 561-9. [Abstract] [Full-text]
146. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer.
     Ann Oncol, 16(7): 1147-51. [Abstract] [Full-text]
147. Malignant triton tumor presenting as a rectal mass in an 11-month-old.
     Pediatr Dev Pathol, 8(2): 235-9. [Abstract] [Full-text]
148. Population-based study of short- and long-term survival from colorectal cancer in Denmark, 1977-1999.
     Br J Surg, 92(7): 873-80. [Abstract] [Full-text]
149. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
     Muscle Nerve, 32(1): 51-60. [Abstract] [Full-text]
150. EphB receptor activity suppresses colorectal cancer progression.
     Nature, 435(7045): 1126-30. [Abstract] [Full-text]
151. Feasibility of colectomy with mini-incision.
     Am J Surg, 190(1): 48-50. [Abstract] [Full-text]
152. Detecting curable disease following hepatectomy for colorectal metastases.
     ANZ J Surg, 75(7): 524-7. [Abstract] [Full-text]
153. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model.
     Hepatology, 42(1): 165-75. [Abstract] [Full-text]
154. Chemopreventive properties of apple procyanidins on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis.
     Carcinogenesis, 26(7): 1291-5. [Abstract] [Full-text]
155. Transformation of immortalized colorectal crypt cells by microcystin involving constitutive activation of Akt and MAPK cascade.
     Carcinogenesis, 26(7): 1207-14. [Abstract] [Full-text]
156. Autofluorescence characterisation of isolated whole crypts and primary cultured human epithelial cells from normal, hyperplastic, and adenomatous colonic mucosa.
     J Clin Pathol, 58(7): 766-74. [Abstract] [Full-text]
157. Primary signet-ring cell carcinoma mimicking segmental Crohn's colitis.
     Dig Liver Dis, 37(7): 537-41. [Abstract] [Full-text]
158. Serum bile acids, programmed cell death and cell proliferation in the mucosa of patients with colorectal adenomas.
     Dig Liver Dis, 37(7): 509-14. [Abstract] [Full-text]
159. Unicystic ameloblastoma presenting in Gardner's syndrome: a case report.
     Br Dent J, 198(12): 747-8. [Abstract] [Full-text]
160. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial.
     Cancer, 104(1): 176-82. [Abstract] [Full-text]
161. Significance and role of early-lesions in experimental colorectal carcinogenesis.
     Chem Biol Interact, 155(1): 1-9. [Abstract] [Full-text]
162. Demographic and pathological characteristics of serrated polyps of colorectum.
     Histopathology, 47(1): 32-40. [Abstract] [Full-text]
163. A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci.
     Histopathology, 47(1): 25-31. [Abstract] [Full-text]
164. Tumour budding as prognostic factor in stage I/II colorectal carcinoma.
     Histopathology, 47(1): 17-24. [Abstract] [Full-text]
165. The utility of capsule endoscopy small bowel surveillance in patients with polyposis.
     Am J Gastroenterol, 100(7): 1498-502. [Abstract] [Full-text]
166. Inhibitory effect of genistein on mouse colon cancer MC-26 cells involved TGF-beta1/Smad pathway.
     Biochem Biophys Res Commun, 333(3): 827-32. [Abstract] [Full-text]
167. Capecitabine as adjuvant treatment for stage III colon cancer.
     N Engl J Med, 352(26): 2696-704. [Abstract] [Full-text]

© 2004-2008 Colorectal Cancer Research Today. All Rights Reserved.